Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published April 26, 2018 | public
Journal Article Open

Epigenetic silencing of miR-125b is required for normal B cell development


Deregulation of several microRNAs (miRs) can influence critical developmental checkpoints during hematopoiesis as well as cell functions, eventually leading to the development of autoimmune disease or cancer. We found that miR-125b is expressed in bone marrow multipotent progenitors and myeloid cells but shut down in the B-cell lineage, and the gene encoding miR-125b lacked transcriptional activation markers in B cells. To understand the biological importance of the physiological silencing of miR-125b expression in B cells, we drove its expression in the B-cell lineage and found that dysregulated miR-125b expression impaired egress of immature B cells from the bone marrow to peripheral blood. Such impairment appeared to be mediated primarily by inhibited expression of the sphingosine-1-phosphate receptor 1 (S1PR1). Enforced expression of S1PR1 or clustered regularly interspaced short palindromic repeats/Cas9–mediated genome editing of the miR-125b targeting site in the S1PR1 3′ untranslated region rescued the miR-125b–mediated defect in B-cell egress. In addition to impaired B-cell egress, miR-125b dysregulation initially reduced pre–B-cell output but later induced pre–B-cell lymphoma/leukemia in mice. Genetic deletion of IRF4 was found in miR-125b–induced B-cell cancer, but its role in oncogenic miR-125b–induced B-cell transformation is still unknown. Here, we further demonstrated an interaction of the effects of miR-125b and IRF4 in cancer induction by showing that miR125b-induced B-cell leukemia was greatly accelerated in IRF4 homozygous mutant mice. Thus, we conclude that physiological silencing of miR-125b is required for normal B-cell development and also acts as a mechanism of cancer suppression.

Additional Information

© 2018 American Society of Hematology. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. Submitted December 29, 2017; Accepted March 5, 2018. The authors thank members of the D.B. laboratory for helpful discussions, Toshio Kitamura (The University of Tokyo) for providing Eμ/miR-125b-Tg mice, and Xun Wang for providing the retro-gRNA-CFP vector. This work was supported by the National Institutes of Health, National Institute of Allergy and Infectious Diseases (RO1AI079243) (D.B.). Authorship: Contribution: G.L. designed research, performed experiments, analyzed results, and wrote the paper; A.Y.-L.S., R.S., Y.O., S.W., J.K.W., P.H., and Y.S. performed experiments; R.C. provided data and discussed the results; and D.B. designed research, discussed results, wrote the paper and provided financial support. The authors declare no competing financial interests.

Attached Files

Published - 1920.full.pdf

Supplemental Material - blood-2018-01-824540-1.pdf


Files (4.1 MB)
Name Size Download all
2.1 MB Preview Download
2.1 MB Preview Download

Additional details

August 19, 2023
August 19, 2023